论文部分内容阅读
目的:研究谷胱甘肽硫转移酶(GSTs)基因多态性与环磷酰胺在难治性肾病综合征的不良反应关系。方法:运用等位基因特异性PCR(ASPCR)和PCR-限制性片段长度多态性(PCR-RFLP)的方法分析谷胱甘肽硫转移酶基因型;参照SFDA的不良反应分析标准分析环磷酰胺在难治性肾病综合征的不良反应。结果:骨髓抑制组和胃肠道反应组含有GSTP1(I/V或V/V)的机率高于无骨髓抑制组和无胃肠道反应组,GSTP1(I/V或V/V)组患者发生骨髓抑制和胃肠道反应机率高于GSTP1(I/I)组患者。结论:环磷酰胺治疗前检测GSTs基因多态性有助于避免骨髓抑制和胃肠道反应的发生。
Objective: To investigate the relationship between glutathione S-transferase (GSTs) gene polymorphism and cyclophosphamide in patients with refractory nephrotic syndrome. Methods: The genotypes of glutathione S-transferase were analyzed by allele-specific PCR (ASPCR) and PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) Amide adverse reactions in refractory nephrotic syndrome. Results: The rates of GSTP1 (I / V or V / V) in the myelosuppressive group and the gastrointestinal group were significantly higher than those in the non-myelosuppressed group and the non-gastrointestinal group. The patients with GSTP1 (I / V or V / V) The incidence of myelosuppression and gastrointestinal reactions was higher in patients with GSTP1 (I / I). Conclusion: The detection of GSTs gene polymorphism before cyclophosphamide treatment can help prevent the occurrence of myelosuppression and gastrointestinal reactions.